Research Article

Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study

Volume: 52 September 2, 2026
EN TR

Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study

Abstract

Candidozyma auris (formerly Candida auris) is an emerging multidrug-resistant fungal pathogen associated with healthcare-associated infections and high mortality. This study evaluated the clinical characteristics, antifungal susceptibility profiles, and risk factors for candidemia and mortality in patients with C. auris isolation. This retrospective cohort study included patients with at least one clinical specimen positive for C. auris between May 2023 and June 2025. Patients were classified as having colonization or infection based on clinical and microbiological criteria. Trend analysis evaluated changes across colonization, non-bloodstream infection, and candidemia, and risk factors for candidemia and mortality were assessed using Firth penalized logistic regression. Forty-nine patients were included (median age, 67 years), of whom 63.3% were in the intensive care unit at the time of isolation. Colonization and infection were identified in 55.1% and 44.9% of patients, respectively, with candidemia being the most common presentation (68.2% of infections). The frequencies of intensive care unit stay, central venous catheter use, and total parenteral nutrition increased significantly from colonization to candidemia (p for trend <0.05). In multivariable analysis, intensive care unit stay (aOR 4.2, p=0.03) and total parenteral nutrition (aOR 6.9, p=0.04) were independently associated with candidemia. All isolates were resistant to fluconazole, echinocandins showed high in vitro activity, and amphotericin B MICs were ≥2 μg/mL in 64.3% of isolates. Overall, in-hospital mortality was 46.9%. Charlson Comorbidity Index, total parenteral nutrition, and clinically significant infection were independently associated with in-hospital mortality.

Keywords

Supporting Institution

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Ethical Statement

Ethical approval was obtained from the Bursa Uludağ University Non-Interventional Clinical Research Ethics Committee (Decision No: 2025/789/14-8). The authors declare no conflict of interest.

References

  1. 1. Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290. doi:10.1371/journal.ppat.1006290
  2. 2. Tsay S, Kallen A, Jackson BR, Chiller TM, Vallabhaneni S. Approach to the investigation and management of patients with Candida auris, an emerging multidrug-resistant yeast. Clin Infect Dis. 2018;66(2):306-311. doi:10.1093/cid/cix744
  3. 3. Kohlenberg A, Monnet DL, Plachouras D, Candida auris Survey Collaborative Group. Increasing number of cases and outbreaks caused by Candida auris in the EU/EEA, 2020 to 2021. Euro Surveill. 2022;27(46):2200846. doi:10.2807/1560-7917.ES.2022.27.46.2200846
  4. 4. Garcia-Bustos V, Puchades F, Alonso-Ecenarro F, et al. Development and validation of the AURIS score for predicting candidaemia in Candidozyma auris-colonised patients in the intensive care unit: a bicentric retrospective cohort study. Lancet Infect Dis. 2026;26(7):671-679. doi:10.1016/S1473-3099(26)00002-2
  5. 5. Jeffery-Smith A, Taori SK, Schelenz S, et al. Candida auris: a review of the literature. Clin Microbiol Rev. 2018;31(1):e00029-17. doi:10.1128/CMR.00029-17
  6. 6. Cortegiani A, Misseri G, Fasciana T, et al. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69. doi:10.1186/s40560-018-0342-4
  7. 7. European Centre for Disease Prevention and Control (ECDC). Survey on the epidemiological situation, laboratory capacity and preparedness for Candidozyma (Candida) auris, 2024. Stockholm: ECDC; 2025. doi:10.2900/2025052
  8. 8. Republic of Türkiye Ministry of Health, General Directorate of Public Health. Candida auris in Healthcare Services. Ankara, Türkiye: Republic of Türkiye Ministry of Health;2025. [Accessed: March 6, 2026]. Available from: https://hsgm.saglik.gov.tr/depo/birimler/bulasici-hastaliklar-ve-erken-uyari-db/Dokumanlar/Afisler-Brosurler/2025/Ek_Saglik_Hizmetlerinde_C._auris.pdf

Details

Primary Language

English

Subjects

Infectious Diseases

Journal Section

Research Article

Publication Date

September 2, 2026

Submission Date

April 15, 2026

Acceptance Date

August 2, 2026

Published in Issue

Year 2026 Volume: 52

APA
Kazak, E., Yilmaz, E., Konak, Z., Çalışır, B., Önal, U., Öztürk Demir, M., Souleiman, E., Yılmaz, H. A., İmer, H., Aydın Tüfekçi, H., Çalışkan, G., Aliyeva, L., Heper, Y., Özakın, C., Ener, B., & Akalın, H. (2026). Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study. Journal of Uludağ University Medical Faculty, 52. https://doi.org/10.32708/uutfd.1930101
AMA
1.Kazak E, Yilmaz E, Konak Z, et al. Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study. Journal of Uludağ University Medical Faculty. 2026;52. doi:10.32708/uutfd.1930101
Chicago
Kazak, Esra, Emel Yilmaz, Zilan Konak, et al. 2026. “Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma Auris Infections: A Single-Center Retrospective Study”. Journal of Uludağ University Medical Faculty 52 (September). https://doi.org/10.32708/uutfd.1930101.
EndNote
Kazak E, Yilmaz E, Konak Z, Çalışır B, Önal U, Öztürk Demir M, Souleiman E, Yılmaz HA, İmer H, Aydın Tüfekçi H, Çalışkan G, Aliyeva L, Heper Y, Özakın C, Ener B, Akalın H (September 1, 2026) Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study. Journal of Uludağ University Medical Faculty 52
IEEE
[1]E. Kazak et al., “Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study”, Journal of Uludağ University Medical Faculty, vol. 52, Sept. 2026, doi: 10.32708/uutfd.1930101.
ISNAD
Kazak, Esra - Yilmaz, Emel - Konak, Zilan - Çalışır, Büşra - Önal, Uğur - Öztürk Demir, Melek - Souleiman, Esma et al. “Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma Auris Infections: A Single-Center Retrospective Study”. Journal of Uludağ University Medical Faculty 52 (September 1, 2026). https://doi.org/10.32708/uutfd.1930101.
JAMA
1.Kazak E, Yilmaz E, Konak Z, Çalışır B, Önal U, Öztürk Demir M, Souleiman E, Yılmaz HA, İmer H, Aydın Tüfekçi H, Çalışkan G, Aliyeva L, Heper Y, Özakın C, Ener B, Akalın H. Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study. Journal of Uludağ University Medical Faculty. 2026;52. doi:10.32708/uutfd.1930101.
MLA
Kazak, Esra, et al. “Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma Auris Infections: A Single-Center Retrospective Study”. Journal of Uludağ University Medical Faculty, vol. 52, Sept. 2026, doi:10.32708/uutfd.1930101.
Vancouver
1.Esra Kazak, Emel Yilmaz, Zilan Konak, Büşra Çalışır, Uğur Önal, Melek Öztürk Demir, Esma Souleiman, Hafize Aysun Yılmaz, Habibe İmer, Hatice Aydın Tüfekçi, Gül Çalışkan, Laman Aliyeva, Yasemin Heper, Cüneyt Özakın, Beyza Ener, Halis Akalın. Clinical Characteristics, Antifungal Susceptibility, and Prognosis of Candidozyma auris Infections: A Single-Center Retrospective Study. Journal of Uludağ University Medical Faculty. 2026 Sep. 1;52. doi:10.32708/uutfd.1930101

ISSN: 1300-414X, e-ISSN: 2645-9027

Creative Commons License
Journal of Uludag University Medical Faculty is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2023